Welcome to our dedicated page for KIORA PHARMACEUTICALS news (Ticker: KPRX), a resource for investors and traders seeking the latest updates and insights on KIORA PHARMACEUTICALS stock.
Kiora Pharmaceuticals Inc (NASDAQ: KPRX) is a clinical-stage biotech company pioneering treatments for orphan retinal diseases through innovative platforms like molecular photoswitch technology and DHODH inhibitors. This page serves as the definitive source for official news and developments related to KIO-301 (vision restoration therapy) and KIO-104 (ocular inflammation treatment).
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones including orphan drug designations, and strategic partnerships advancing retinal disease therapies. Our curated collection features press releases on Phase 2 trial outcomes, manufacturing agreements, and peer-reviewed research collaborations.
Key content categories include updates on inherited retinal degeneration treatments, non-steroidal anti-inflammatory developments, and regulatory pathway advancements. All materials maintain strict compliance with financial disclosure standards while prioritizing accessibility for both professional and public audiences.
Bookmark this page for streamlined access to Kiora's latest scientific advancements and corporate announcements. Regularly updated content ensures you stay informed about critical developments in vision-restoring therapies and ocular inflammation management.
Kiora Pharmaceuticals (NASDAQ: KPRX) announced on October 30, 2025 that it joined Global Genes' RARE-X Vision Consortium, a corporate‑nonprofit collaboration to accelerate research and development of therapies for rare ocular disorders.
The consortium will build a de‑identified, individual‑level global data repository to support patient identification and recruitment, define meaningful outcome measures by aggregating functional, structural, and patient‑reported data, and promote inclusive study design with patient input. Kiora's CEO, Brian Strem, said the collaboration aims to increase the probability of advancing Kiora's experimental inherited retinal disease therapy toward patients.
Kiora Pharmaceuticals (NASDAQ: KPRX) will participate in two ophthalmology events in October 2025 to discuss its development pipeline and industry trends. Maxim Growth Summit in New York: Brian M. Strem, PhD, President and CEO, will speak on an ophthalmology panel titled "A vision of innovation" on October 22, 2025 at 3:00 PM EDT (panel overview link: maximgrp.com/2025-growth-summit).
Eyecelerator @ AAO 2025 in Orlando: Eric Daniels, MD, MBA, Chief Development Officer, will present in the Poster Retina Showcase on October 16, 2025 at 1:45 PM EDT (program link: eyecelerator.com/aao-2025-program).
Kiora Pharmaceuticals (NASDAQ:KPRX) announced that CFO Melissa Tosca will present the company's pipeline of therapies for inherited and inflammatory retinal diseases at the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The presentation is scheduled for September 5th, 2025, at 7:00 am EDT. Investors can access the presentation through the company's investor relations website, where it will remain available on-demand for 90 days.
Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q2 2025 financial results and pipeline updates for retinal disease treatments. The company initiated two Phase 2 clinical trials: KLARITY for KIO-104 (retinal inflammation) and ABACUS-2 for KIO-301 (retinitis pigmentosa). Kiora secured a potential $110M partnership with Senju Pharmaceutical for KIO-301 development in Asia.
Financial highlights include a $20.7M cash position, with additional $2.4M in collaboration receivables and $0.7M in tax credits. The company reported a net loss of $2.2M in Q2 2025, unchanged from Q2 2024. R&D expenses increased to $2.6M (before $1.7M in reimbursements), while G&A expenses decreased to $1.4M. Cash runway extends into late 2027, beyond anticipated clinical trial readouts.
Kiora Pharmaceuticals (NASDAQ: KPRX) has announced its participation in the upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. President and CEO Brian M. Strem, Ph.D. will present the company's pipeline of therapies focused on inherited and inflammatory retinal diseases.
The presentation is scheduled for Wednesday, August 13, 2025, at 7:00 am EDT. Investors can access the presentation through Kiora's investor relations website, with the replay remaining available for 90 days following the event.
Vicarious Surgical (NYSE: RBOT) has appointed Stephen From as its new Chief Executive Officer and Board member, effective August 7, 2025. Current CEO and Co-Founder Adam Sachs will transition to the role of President while remaining on the Board. From brings over 20 years of healthcare and financial industry leadership experience, most recently serving as CEO of Aruna Bio.
From's extensive background includes serving as President, CEO, and Executive Chairman of Kiora Pharmaceuticals, where he led the company through its IPO and multiple acquisitions. He previously held positions as CFO of Centelion SAS and worked in investment banking at Bank of America Securities and Robertson Stephens.
As part of his appointment, From will receive a stock option award for 297,600 shares of Class A common stock, vesting over four years, as a material inducement to his employment.
Kiora Pharmaceuticals (NASDAQ: KPRX) has been granted US Patent No. 12,364,680 for KIO-104, expanding its protection for treating various ocular diseases. The patent covers treatment applications including ocular inflammation, uveitis, age-related macular degeneration, and refractive surgery complications, extending market exclusivity until 2043.
The company is currently conducting a Phase 2 clinical trial (KLARITY study) investigating KIO-104 in up to 28 patients at two dose levels for inflammatory retinal diseases, including posterior non-infectious uveitis and diabetic macular edema. KIO-104 functions by inhibiting the DHODH enzyme, reducing T-cell replication and inflammation.
Kiora Pharmaceuticals (NASDAQ: KPRX) presented promising preclinical data for KIO-104, their novel DHODH inhibitor, at ARVO 2025. The study demonstrated significant reduction in scar formation for treating proliferative vitreoretinopathy (PVR), the leading complication following retinal detachment surgery.
Key findings from the rabbit model study showed: The high dose group (10 μg/eye) completely prevented scar formation in all subjects. The low dose group (1 μg/eye) showed reduced scar formation with only 9 retinal scars in 2 of 6 rabbits, with mean scar length of 43 ± 16 μm. The control group developed 20 retinal scars in 4 of 6 animals, with mean scar length of 110 ± 28 μm.
KIO-104 is currently in Phase 2 clinical trials for macular edema treatment in patients with diabetic retinopathy and posterior non-infectious uveitis.
FAQ
What is the current stock price of KIORA PHARMACEUTICALS (KPRX)?
What is the market cap of KIORA PHARMACEUTICALS (KPRX)?
